The assessment of fluid biomarkers of comorbid neuropathologies may augment hallmark biological indicators of AD (e.g., amyloid-β and phosphorylated tau (Jack et al., 2024)) to provide mechanistic insight into the multifactorial disease process on cognitive outcomes. This evidence concerns the gene MAPT and Alzheimer disease.